Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506773 · ClinicalTrials.gov registry record
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
A clinical trial, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- 79
- Enrollment target
NCT06506773: Completed study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06506773 is a clinical trial that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06506773 has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2025-11-27 |
What the finished NCT06506773 record still lists
NCT06506773 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 79 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06506773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06506773 about?
NCT06506773 is a clinical study titled "Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)". The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
What is the current status of trial NCT06506773?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2024-07-09. Estimated completion is 2025-11-27.
Who is sponsoring clinical trial NCT06506773?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI